Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Molecular Structure in Zika Virus May Lead to Disease-Causing RNAs

By University of Colorado Anschutz | November 11, 2016

Molecular structure in Zika virus leads to potentially disease-causing RNAs.

Researchers, led by scientists at the University of Colorado School of Medicine, have found basic molecular processes used by the Zika virus to “hijack” the cells that it infects and potentially how it makes molecules that are directly linked to disease.

The discovery, published in the journal Science, shows that a part of the Zika virus’s RNA genome folds up into a complex structure and that this structure leads to the production of smaller RNAs that in related viruses are directly linked to disease.

Viruses cannot reproduce on their own, they must infect cells and “hijack” the cell’s biological machinery in order to make more copies of themselves. To do this, viruses use many molecular strategies. 

Zika is an example of a virus that does not store its genome in DNA, rather it uses a related molecule called the viral genomic RNA. Viruses related to Zika, such as West Nile and Dengue, are known to produce a set of smaller RNAs during infection (in addition to the long genomic RNA) that have been directly linked to disease. This process had not been explored with Zika virus until this study.

The findings of this study show that Zika infection leads to the production of these smaller RNAs in several types of cells. The researchers show that part of the Zika genomic RNA “folds up” into a complex structure that interacts with and blocks a powerful cellular enzyme that normally destroys RNA, and the researchers used an advanced technique called x-ray crystallography to solve the structure of this folded-up RNA segment. By altering the Zika virus genomic RNA, the team was able to disrupt this structure and eliminate the production of the potentially disease-causing small RNAs.

Jeffrey Kieft, Ph.D., professor of biochemistry and molecular genetics, led a team that consisted of scientists at the University of Colorado School of Medicine (Aurora, CO), the Advanced Light Source at the Lawrence Berkeley National Laboratory (Berkeley, CA), and the University of Texas Medical Branch (Galveston, TX). He is the corresponding author of the article, published in the journal Science. Benjamin Akiyama, Ph.D., a member of Kieft’s Lab, was the lead author on the study. 

“The first step is stopping any process that causes disease is to understand that process in detail, preferably at the molecular level.” said Kieft, who is also a member of the University of Colorado RNA BioScience Initiative. “Based on what we knew about related viruses, there was reason to suspect that Zika virus infection would result in potentially disease-causing RNAs, but we couldn’t be sure. Now, having observed them and the molecular structures involved, we can ask new questions about the fundamental molecular processes Zika uses to take over a cell and cause disease.” 

The findings could also inform ongoing efforts to develop a vaccine or other anti-Zika therapeutics. Also, because Zika is closely related to other dangerous viruses such as Dengue, West Nile, Japanese Encephalitis and Yellow Fever, the discoveries may be broadly applicable to understanding these viruses and may help in efforts to stop them. 

Faculty at the University of Colorado School of Medicine work to advance science and improve care. These faculty members include physicians, educators and scientists at University of Colorado Health, Children’s Hospital Colorado, Denver Health, National Jewish Health, and the Denver Veterans Affairs Medical Center. The school is located on the Anschutz Medical Campus, one of four campuses in the University of Colorado system.

(Source: EurekAlert!)

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE